VERAXA Biotech AG (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has announced the appointment of Raju Willener as chief financial officer, effective immediately. The move brings a veteran of global finance with over three decades of experience to the helm of the company's financial operations, a step that underscores VERAXA's focus on advancing its proprietary BiTAC technology platform and oncology pipeline.
Willener will report directly to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to play a pivotal role in shaping the company's capital strategy, identifying strategic opportunities, and supporting the continued development of its clinical programs. His appointment comes as VERAXA seeks to position itself in the competitive field of antibody-based therapeutics, where financial acumen is as critical as scientific innovation.
Before joining VERAXA, Willener served as director of corporate development at Exentis Group AG, where he was later appointed CFO in 2025. In that role, he led mergers and acquisitions initiatives, financial strategy, and key corporate functions. His earlier career included senior executive and investment positions overseeing corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management. This track record of managing large-scale financial operations is expected to be instrumental as VERAXA navigates the complexities of drug development and commercialization.
The importance of this appointment extends beyond the company's internal structure. For investors and the biotechnology industry, the addition of a CFO with deep capital markets experience signals that VERAXA is prioritizing financial discipline and strategic growth. The company is developing bispecific T cell engagers, bispecific ADCs, and other innovative formats, all rooted in research from the European Molecular Biology Laboratory (EMBL). With the BiTAC technology platform at the core of its pipeline, VERAXA aims to bring next-generation cancer therapies to patients, a mission that requires substantial funding and savvy financial management.
Willener's role will likely involve navigating public markets and potential partnerships, areas where his background in investment banking and asset management could prove valuable. His experience with portfolios exceeding CHF 30 billion suggests a capability to handle the scale of investment needed to advance multiple drug candidates through clinical trials. For the broader industry, this move reflects a growing trend of biotech companies bolstering their executive teams with financial experts to weather market volatility and secure long-term viability.
As VERAXA progresses, the appointment of a seasoned CFO is a clear indication of its commitment to robust corporate governance and strategic financial planning. The company's focus on antibody-based cancer therapies remains at the forefront, and with Willener on board, it is better positioned to capitalize on opportunities that may arise. Investors and industry observers will be watching closely to see how this leadership change impacts VERAXA's trajectory in the coming months. For more information on VERAXA Biotech, visit the company's newsroom at http://nnw.fm/VRXA. The full press release is available at https://nnw.fm/jcHOU.
